Aeglea BioTherapeutics Announces Leadership Transition and C

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

Related Keywords

Texas , United States , Jim Kastenmayer , Aeglea Biotherapeutics , Michael Hanley , Russellj Cox , Anthony Quinn , Prnewswire Aeglea Biotherapeutics Inc , Nasdaq , Anthony , Prioritizing Resources , Ongoing Phase , Interim Clinical Data Expected , Board Member , Stepped Down , His Current Positions , Extend Runway , Classical Homocystinuria , Drug Designation , Pediatric Disease , Rare Pediatric Disease , Breakthrough Therapy , Nc ,